Weiler Peter J. 4

What Happened

• Peter J. Weiler, Chief Financial Officer of Edesa Biotech, was granted 64,609 restricted share units (RSUs) on 2026-05-27. The filing reports an acquisition at $0.00 per share (total reported value $0), reflecting a compensation award rather than a cash purchase.

Key Details

• Transaction date and type: 2026-05-27 — Award/Grant (code A) of 64,609 RSUs, reported on Form 4 filed 2026-05-29 (timely filing).
• Price reported: $0.00 per share; total reported value $0.
• Shares owned after the transaction: Not specified in the provided filing.
• Vesting/footnote: Footnote F1 — the RSUs were issued under the Issuer’s 2019 Equity Incentive Compensation Plan and vest monthly in equal proportions over 36 months beginning on the grant date.
• No tax-withholding sale or immediate disposition of shares was reported.

Context

• RSUs are a form of equity compensation that convert to actual shares as they vest; this award does not represent an open-market purchase or sale and does not immediately change share ownership tradable on the market.
• Such grants are commonly used for executive compensation and are typically intended to align management incentives with long-term shareholder value; the filing is informational and does not, by itself, indicate trading intent.